0001104659-24-031806.txt : 20240307
0001104659-24-031806.hdr.sgml : 20240307
20240307132720
ACCESSION NUMBER: 0001104659-24-031806
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240305
FILED AS OF DATE: 20240307
DATE AS OF CHANGE: 20240307
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sabba Stephen L
CENTRAL INDEX KEY: 0001442372
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33093
FILM NUMBER: 24729315
MAIL ADDRESS:
STREET 1: DORSET MANAGEMENT CORP
STREET 2: 485 UNDERHILL BLVD SUITE 205
CITY: SYOSSET
STATE: NY
ZIP: 11791
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: LIGAND PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000886163
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 770160744
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3911 SORRENTO VALLEY BLVD
STREET 2: SUITE 110
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-550-7500
MAIL ADDRESS:
STREET 1: 3911 SORRENTO VALLEY BLVD
STREET 2: SUITE 110
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
tm248239-1_4seq1.xml
OWNERSHIP DOCUMENT
X0508
4
2024-03-05
0
0000886163
LIGAND PHARMACEUTICALS INC
LGND
0001442372
Sabba Stephen L
DORSET MANAGEMENT CORP
485 UNDERHILL BLVD SUITE 205
SYOSSET
NY
11791
1
0
0
0
0
Common Stock
2024-03-05
4
M
0
2893
0.00
A
30819
D
Common Stock
2024-03-05
4
S
0
1893
74.30
D
28926
D
Non-Qualified Stock Option (right to buy)
67.53
2024-03-05
4
M
0
2893
0
D
2024-06-04
Common Stock
2893
419
D
These securities, as represented in Column 5, include a grant of 1,142 restricted share units approved by the Board of Directors of the Company at the 2023 Meeting, which shares will vest in full on the earlier of (a) the date of the next annual meeting of the Company stockholders following the grant date or (b) on the first anniversary of the grant date. They also properly reflect adjustments from the OmniAb Inc. separation from the Issuer. The Shares referenced in Column 5 of Table I as disposed of on the Form 4 filed 5/10/23 for this Reporting Person inadvertently failed correctly to reflect those adjustments. That number should have been 26,784.
These securities, as represented in Column 5, were acquired by a grant of 3,312 shares by the Board of Directors of the Company at the 2014 Meeting. That grant vested in full on the first anniversary of the grant date or immediately (x) upon a change in control or a hostile takeover of the Company or (y) the death or permanent disability of the grantee if still serving at that time.
This Option was previously reported on the Form 4 filed 6/6/14 as a Grant of 3,312 shares, which vested in full on April 24, 2015, at an exercise price of $67.53 per share, but was adjusted pursuant to the OmniAb Inc. separation from the Issuer.
By: /s/ Stephen L. Sabba
2024-03-07